ArticleBlood and lymphatic cancer : targets and therapy2026
Construction and Validation of an N7-Methylguanosine-Related Prognostic Model for Acute Myeloid Leukemia.
Article in Blood and lymphatic cancer : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Increasing evidence suggests the involvement of N7-methylguanosine (m7G) in cancer biology. However, its role in acute myeloid leukemia (AML) remains unclear. Herein, bioinformatics approaches were used to obtain insights for AML risk stratification and treatment. Patients and Methods: Data from TCGA-LAML, GSE114868, and GSE37642 were analyzed. Differentially expressed genes from GSE114868 were intersected with key module genes identified via weighted gene co-expression network analysis. The identified genes underwent univariate and multivariate Cox regression analyses and machine learning to identify prognostically relevant m7G-related genes (m7G-RGs). Moreover, a prognostic risk model was built and validated, and its association with immune infiltration was evaluated. Model performance was compared with the European LeukemiaNet (ELN) 2022 genetic risk stratification system. Expression levels of key genes were analyzed in GSE114868 and validated in independent clinical samples. Results: A prognostic risk model was developed based on seven m7G-RGs ( Conclusion: We developed and validated a novel m7G-related prognostic model for AML based on seven genes. The findings suggest a potential association among m7G modification, AML prognosis, and the tumor immune microenvironment. The model showed complementary value to the ELN 2022 risk stratification by improving risk assessment among patients classified as intermediate risk. As a retrospective, computational study, prospective validation is required. The identified m7G-RGs warrant further investigation as potential biomarkers or therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.